Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD06-04 CAR-T in autoantibody-mediated autoimmune diseases
NCT06548620Phase 1Withdrawn
- Sponsor
- Bioheng Therapeutics
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD06-04 in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and 5 more, sponsored by Bioheng Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 2 years, Serious Adverse Events at 2 years and 1 more. Planned start Aug 2024; status: withdrawn.
02
Drugs
RD06-04
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)idiopathic inflammatory myopathy (IIM)Sjögren's syndrome
Beyond the preview
Go deeper on NCT06548620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548620.